相关实验视频

Updated: Jun 12, 2026

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

A Protocol for Using Gene Set Enrichment Analysis to Identify the Appropriate Animal Model for Translational Research

Published on: August 16, 2017

通过单个样本基因组丰富分析识别COVID-19亚型,并为敏感药物选择提供指导

Nan Xiong^1,2, Qiangming Sun^1,3

¹Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.

Journal of medical virology

|March 4, 2024

概括

这项研究使用基因表达将2019年新冠病毒病 (COVID-19) 患者分为免疫力高和免疫力低的组. 这种基于免疫的聚类可能会指导个性化的COVID-19治疗策略和药物开发.

科学领域:

免疫学免疫学免疫学
基因组学就是基因组学.
计算生物学计算生物学

背景情况:

新型冠状病毒疾病2019 (COVID-19) 给公共卫生带来了重大挑战.
了解宿主免疫反应对于有效的COVID-19治疗至关重要.
目前的治疗策略可能会从基于免疫特征的患者分层中受益.

研究的目的:

开发一种基于单个样本基因组丰富分析 (ssGSEA) 成绩的Covid-19患者聚类方法.
调查这种集群方法在指导COVID-19治疗和药物开发方面的潜力.

主要方法:

利用了来自COVID-19患者鼻口样本的ssGSEA得分.
集群样本分为两个组:免疫力高 (免疫力-H) 和免疫力低,基于免疫细胞分数和炎症通路活性.
在免疫H组中确定了上调基因和枢纽基因.
使用DGIdb数据库预测潜在的药物针对已识别的枢纽基因.

主要成果:

成功地将COVID-19患者分为不同的免疫特征 (免疫力-H和免疫力-低).
免疫H组表现出丰富的炎症通路和更高的免疫细胞分数.
鉴定出在免疫H组上调的特定基因,表明药物反应差异.
发现了免疫H组的潜在治疗标和药物,特别是那些涉及中性粒细胞的药物.

结论:

基于ssGSEA的聚类方法有效地根据免疫状态对COVID-19患者进行分层.
这种免疫分层对优化免疫H组的抗炎治疗有希望.
已识别的基因特征和潜在的药物标为COVID-19治疗中个性化医疗提供了途径.
这种方法可以帮助开发和管理针对COVID-19患者的向疗法.

关键词:

免疫力-H组免疫力鼻/喉抽样样本样本样本样本样本样本单样样本基因组丰富分析治疗冠状病毒疾病 2019年

更多相关视频

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

相关概念视频

Single Nucleotide Polymorphisms-SNPs

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...